PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97760716 |
Filing Date: 01/19/2023 |
Input Field |
Entered |
TEAS Plus | YES |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\977\607\97760716\xml1 \ FTK0002.JPG |
*SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
LITERAL ELEMENT | PRIORIX |
*COLOR MARK | NO |
*COLOR(S) CLAIMED (If applicable) |
|
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of PRIORIX followed by three triangles of the same size. |
PIXEL COUNT ACCEPTABLE | YES |
PIXEL COUNT | 944 x 250 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | GlaxoSmithKline Biologicals SA |
*MAILING ADDRESS | Rue de l'Institut 89 |
*CITY | Rixensart |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Belgium |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
B-1330 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
*TYPE | CORPORATION |
* STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Belgium |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
*INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Vaccines |
*FILING BASIS | SECTION 1(a) |
FIRST USE ANYWHERE DATE | At least as early as 08/01/2022 |
FIRST USE IN COMMERCE DATE | At least as early as 08/01/2022 |
SPECIMEN FILE NAME(S) | |
ORIGINAL PDF FILE | SPE0-15251561-20230117122 754677441_._PRIORIX_Packa ging.pdf |
CONVERTED PDF FILE(S) (1 page) |
\\TICRS\EXPORT18\IMAGEOUT 18\977\607\97760716\xml1\ FTK0003.JPG |
SPECIMEN DESCRIPTION | photo of packaging |
WEBPAGE URL | None Provided |
WEBPAGE DATE OF ACCESS | None Provided |
ADDITIONAL STATEMENTS SECTION | |
*TRANSLATION (if applicable) |
|
*TRANSLITERATION (if applicable) |
|
*CLAIMED PRIOR REGISTRATION (if applicable) |
The applicant claims ownership of active prior U.S. Registration Number(s) 4834274. |
*CONSENT (NAME/LIKENESS) (if applicable) |
|
*CONCURRENT USE CLAIM (if applicable) |
|
ATTORNEY INFORMATION | |
NAME | Christopher M. Hanes |
ATTORNEY DOCKET NUMBER | 84199316 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | GSK |
INTERNAL ADDRESS | LBP |
STREET | 410 Blackwell Street |
CITY | Durham |
STATE | North Carolina |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 27701 |
PHONE | 919-450-7041 |
EMAIL ADDRESS | trademarks@gsk.com |
OTHER APPOINTED ATTORNEY | Elizabeth K. Rucki |
CORRESPONDENCE INFORMATION | |
NAME | Christopher M. Hanes |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Plus |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 250 |
*TOTAL FEES DUE | 250 |
*TOTAL FEES PAID | 250 |
SIGNATURE INFORMATION | |
* SIGNATURE | /Christopher M. Hanes/ |
* SIGNATORY'S NAME | Christopher M. Hanes |
* SIGNATORY'S POSITION | Attorney of record, North Carolina bar member |
SIGNATORY'S PHONE NUMBER | 919-450-7041 |
* DATE SIGNED | 01/17/2023 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97760716 |
Filing Date: 01/19/2023 |
The applicant's current Correspondence Information: |
Christopher M. Hanes |
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|